Abstract
Pain remains a major unmet health need. Rising opioid prescribing has not reduced population pain and has directly contributed to increased morbidity and mortality. Opioid use disorder (OUD) and pain frequently coexist. Many people with OUD experience acute and chronic pain and a substantial proportion of patients prescribed opioids develop OUD. We have contributed to this problem. In this Position Paper, we defend the idea that we must urgently redefine pain medicine as a frontline discipline in opioid use disorder prevention and recovery. Pain management must be reframed as part of the solution for people with or at risk of OUD. Core principles include: early identification of OUD and psychiatric comorbidity, routine incorporation of trauma-informed, stigma-reducing communication and shared decision-making; continuation of opioid agonist therapy during acute care; use of tailored multimodal, opioid-sparing analgesia; and perioperative planning with addiction and primary care follow-up. At a system level, we recommend multidisciplinary opioid stewardship, clear limits on opioid indication, dose and duration, diversion-mitigation strategies and policy changes such as reduced pack sizes and limiting indications for prolonged-released opioids. Research priorities include qualitative studies of lived experience, inclusion of patient-reported outcomes in trials and big-data analyses of prescribing to identify targets for intervention. Integrating clinical best practice, stigma-aware care and system reforms can reduce harm while ensuring equitable, effective pain relief for people with pain and those with or at risk of OUD.
Significance: This position paper synthesises clinical, psychosocial and system-level strategies to manage pain in people with or at risk of OUD. It emphasises our unique responsibility by learning from failures, and constructively sees the future. Treatment continuity, trauma-informed and stigma-reducing communication, integrated care, interdisciplinary coordination and opioid stewardship policies are no longer optional. These recommendations aim to reduce harms, improve pain and mental-health out-comes and guide clinicians and policymakers toward better and more equitable care.
References
1. Azevedo, L. F., A. Costa-Pereira, L. Mendonça, C. C. Dias, and J. M. Castro-Lopes. 2016. “The Economic Impact of Chronic Pain: A Nationwide Population-Based Cost-Of-Illness Study in Portugal.” European Journal of Health Economics 17: 87–98. https://doi.org/10. 1007/s10198-014-0659-4.
2. Darnall, B. D., K. A. Edwards, R. E. Courtney, M. S. Ziadni, L. E. Simons, and L. E. Harrison. 2023. “Innovative Treatment Formats, Technologies, and Clinician Trainings That Improve Access to Behavioral Pain Treatment for Youth and Adults.” Frontiers in Pain Research (Lausanne) 4: 1223172. https://doi.org/10.3389/fpain.2023.1223172.
3. Forget, P., and W. Hauser. 2023. “Europe Has Much to Do to Improve the Quality of and Access to Safe Pain Management.” Lancet 401: 1651. https://doi.org/10.1016/S0140-6736(23)00669-4.
4. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. 2011. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press. https://doi.org/10.17226/13172.
5. European Union Drugs Agency. 2025. “European Drug Report 2025: Trends and Developments.”
6. Kolodny, A., and R. M. Bohler. 2024. “Screened Out—How a Survey Change Sheds Light on Iatrogenic Opioid Use Disorder.” New England Journal of Medicine 391: 2183–2184. https://doi.org/10.1056/NEJMp2410911.
7. Wilton, J., Y. Abdia, M. Chong, et al. 2021. “Prescription Opioid Treatment for Non-Cancer Pain and Initiation of Injection Drug Use: Large Retrospective Cohort Study.” BMJ 375: e066965. https://doi.org/ 10.1136/bmj-2021-066965.
8. Forget, P. 2021. “Opioid Treatment for Non-Cancer Pain: We Need a Comprehensive Approach.” BMJ (Clinical Research ed.) 375: n3045. https://doi.org/10.1136/bmj.n3045.
9. Kim, J. J., D. Hayati, M. Zamany, et al. 2025. “Chronic Pain Among Primary Fentanyl Users: The Concept of Self-Medication.” European Journal of Pain 29: e4753. https://doi.org/10.1002/ejp.4753.
10. Yang, J., M. Jung, L. Picco, et al. 2024. “Pain in People Seeking and Receiving Opioid Agonist Treatment: A Systematic Review and Meta-Analysis of Prevalence and Correlates.” Addiction 119: 1879–1901. https://doi.org/10.1111/add.16574.
11. Häuser, W., E. Buchser, D. P. Finn, et al. 2021. “Is Europe Also Facing an Opioid Crisis?—A Survey of European Pain Federation Chapters.” European Journal of Pain 25: 1760–1769. https://doi.org/10.1002/ ejp.1786.
12. Thomas, K. H., M. N. Dalili, H. Cheng, et al. 2024. “Prevalence of Problematic Pharmaceutical Opioid Use in Patients With Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis.” Addiction 119: 1904–1922. https://doi.org/10.1111/add.16616.
13. Mehta, V., and R. Langford. 2009. “Acute Pain Management in Opioid Dependent Patients.” Reviews in Pain 3: 10–14. https://doi.org/10.1177/204946370900300204.
14. Van Boekel, L. C., E. P. M. Brouwers, J. Van Weeghel, and H. F. L. Garretsen. 2013. “Stigma Among Health Professionals Towards Patients With Substance Use Disorders and Its Consequences for Healthcare Delivery: Systematic Review.” Drug and Alcohol Dependence 131: 23–35. https://doi.org/10.1016/j.drugalcdep.2013.02.018.
15. Jones, C. M., and E. F. McCance-Katz. 2019. “Co-Occurring Substance Use and Mental Disorders Among Adults With Opioid Use Disorder.” Drug and Alcohol Dependence 197: 78–82. https://doi.org/10.1016/j. drugalcdep.2018.12.030.
16. Volkow, N. D., G. F. Koob, and A. T. McLellan. 2016. “Neurobiologic Advances From the Brain Disease Model of Addiction.” New England Journal of Medicine 374: 363–371. https://doi.org/10.1056/NEJMr a1511480.
17. Goesling, J., D. J. Clauw, and A. L. Hassett. 2013. “Pain and Depression: An Integrative Review of Neurobiological and Psychological Factors.” Current Psychiatry Reports 15: 421. https://doi.org/10.1007/s1192 0-013-0421-0.
18. Defrin, R., K. Ginzburg, Z. Solomon, et al. 2008. “Quantitative Testing of Pain Perception in Subjects With PTSD—Implications for the Mechanism of the Coexistence Between PTSD and Chronic Pain.” Pain 138: 450–459. https://doi.org/10.1016/j.pain.2008.05.006.
19. Bair, M. J., R. L. Robinson, W. Katon, and K. Kroenke. 2003. “Depression and Pain Comorbidity: A Literature Review.” Archives of Internal Medicine 163: 2433. https://doi.org/10.1001/archinte.163.20.2433.
20. Meda, R. T., S. P. Nuguru, S. Rachakonda, S. Sripathi, M. I. Khan, and N. Patel. 2022. “Chronic Pain-Induced Depression: A Review of Prevalence and Management.” Cureus 14: 28416. https://doi.org/10.7759/cureus.28416.
21. Cherkin, D. C., K. J. Sherman, B. H. Balderson, et al. 2016. “Effect of Mindfulness-Based Stress Reduction vs Cognitive Behavioral Therapy or Usual Care on Back Pain and Functional Limitations in Adults With Chronic Low Back Pain: A Randomized Clinical Trial.” JAMA 315: 1240–1249. https://doi.org/10.1001/jama.2016.2323.
22. Garland, E. L., J. Hudak, A. W. Hanley, and Y. Nakamura. 2020. “Mindfulness-Oriented Recovery Enhancement Reduces Opioid Dose in Primary Care by Strengthening Autonomic Regulation During Meditation.” American Psychologist 75: 840–852. https://doi.org/10. 1037/amp0000638.
23. Vadeghani, A. T., M. Grant, and P. Forget. 2024. “Perioperative Pain Management Interventions in Opioid User Patients: An Overview of Reviews.” BMC Anesthesiology 24: 310. https://doi.org/10.1186/s12871-024-02703-6.
24. Meyer-Frießem, C. H., E. Lipke, S. Weibel, et al. 2022. “Perioperative Ketamine for Postoperative Pain Management in Patients With Preoperative Opioid Intake: A Systematic Review and Meta-Analysis.” Journal of Clinical Anesthesia 78: 110652. https://doi.org/10.1016/j.jclin ane.2022.110652.
25. Adams, T. J., J. T. W. Teck, A. Baldacchino, and P. Forget. 2025. “An Impact Evaluation of the Scottish Take-Home Naloxone Programme.” Health Policy and Technology 14: 101072. https://doi.org/10.1016/j.hlpt. 2025.101072.
26. Forget, P., C. Patullo, D. Hill, et al. 2022. “System-Level Policies on Appropriate Opioid Use, a Multi-Stakeholder Consensus.” BMC Health Services Research 22: 329. https://doi.org/10.1186/s12913-022-07696-x.
27. Medicines and Healthcare products Regulatory Agency. 2025. “Prolonged-Release Opioids: Removal of Indication for Relief of Post-Operative Pain (No. 18(8)), MHRA Safety Update.”
28. Adams, T. J., N. Levy, P. E. Macintyre, and P. Forget. 2024. “Limit Packaging Size for Opioids Prescribed at Post-Surgical Discharge.” Lancet 403: 1745. https://doi.org/10.1016/S0140-6736(23)02021-4.
29. Soliman, N., X. Moisset, M. C. Ferraro, et al. 2025. “Pharmacotherapy and Non-Invasive Neuromodulation for Neuropathic Pain: A Systematic Review and Meta-Analysis.” Lancet Neurology 24: 413–428. https://doi. org/10.1016/S1474-4422(25)00068-7.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Duncan Ritchie, Patrice Forget (Autor/a)
